BioMerica Inc. (BMRA)

[Fress]

$PULM their pulmonary technology is what we need ASAP. Many elderly people infected with the covid virus need serious assistance with pulmonary functions many are hooked up to machines for days and weeks. Even if they seem able to walk they all need drugs and devices to help them breath once back home. Also the coronavirus have ways to embed deep in the lungs.

$PULM the key about defeating this virus is the ability for any drug to get deep into the lungs. The lung cells are getting destroyed if the drugs don’t get there to stop the deterioration. These covid viral cells are able to permanently damage lung cells and lung functions for life. This is why technology like this is so paramount.

Our innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands the universe of inhalable drug therapies.

iSPERSE™ is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for highly efficient drug delivery and deep penetration into the lungs.

iSPERSE™ can efficiently deliver small molecules, drug combinations, peptides, proteins, and nucleic acids via the respiratory system for the treatment of both respiratory and non-respiratory diseases.

Market cap is 20 Million Look for a break of 52 week high $3.01 market cap is only around 25M$ in spite two major deals already inked with Cipla and $JNJ PULM will triple in a blink of an eye from these levels.

http://filecache.investorroom.com/mr5ir_pulmatrix/201/Pulmatrix%20-%20Corporate%20Presentation%20March%202020.pdf

$BMRA
$PULM